Why It Matters
Alnylam Pharmaceuticals Inc. is lobbying on Medicare home infusion coverage, implementation of the Inflation Reduction Act (IRA), most-favored-nation (MFN) drug pricing, and pharmaceutical supply chain tariffs as Congress and the administration consider policies affecting prescription drug coverage and pricing.
The company's lobbying disclosures identify H.R. 4993, the Joe Fiandra Access to Home Infusion Act of 2025, which the committee ordered reported by a 41-0 vote on Dec. 10, 2025. Another measure, H.R. 1672, the Maintaining Investments in New Innovation Act, would change Medicare drug price negotiation eligibility for certain genetically targeted therapies.
By the Numbers
Alnylam's in-house third-quarter lobbying report listed $470,000 in expenditures for July 1 through Sept. 30, up $20,000 (4.4%) from the second quarter and $80,000 (20.5%) from the third quarter of 2025.
Five outside firms also reported lobbying income from Alnylam during the third quarter: SplitOak Strategies LLC and Todd Strategy Group each reported $60,000; LMH Strategic Solutions LLC reported $50,000; Tiber Creek Group Inc. reported $60,000; and Capitol Counsel LLC reported $30,000. The five firms reported $260,000 in lobbying income, bringing Alnylam's combined third-quarter total across all six registrants to $730,000.
The in-house filing identified three lobbyists: Deirdre Parsons, vice president of public policy and government relations; Curtis Rhyne, director of government relations; and Maggie Herman, director of government relations. Rhyne previously spent approximately 11 years and nine months working in multiple Republican House offices. Herman previously served in the offices of Rep. Mikie Sherrill (D-NJ) and former Rep. Dan Kildee (D-MI).
Broader Context
H.R. 1672, Maintaining Investments in New Innovation Act
Introduced Feb. 27, 2025, by Rep. Don Davis (D-NC), H.R. 1672 would establish a longer period before certain genetically targeted drugs become eligible for Medicare price negotiation under the IRA. The legislation would require qualifying products to have been approved for at least 11 years, rather than the seven-year threshold generally applicable to qualifying small-molecule drugs.
The measure was referred to the House Energy and Commerce and Ways and Means committees. The supplied legislative record identifies no subsequent committee action or Senate companion.
MFN drug pricing and supply chain tariffs
President Donald Trump issued an executive order in May 2025 directing federal agencies to pursue MFN prescription drug pricing, which would tie certain U.S. drug prices to lower prices paid in other countries. A White House fact sheet issued Dec. 19, 2025, described subsequent administration actions implementing that policy.
An April 2 proclamation established tariff treatment for imported pharmaceutical products, including a stated 100% ad valorem duty on certain patented pharmaceuticals, with different effective dates and exceptions depending on the product category.
Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Stephen J. Ubl argued in a published opinion piece that linking U.S. prescription drug prices to prices in other countries could reduce investment in pharmaceutical research and limit patient access to new treatments.
The Information Technology and Innovation Foundation (ITIF) similarly argued in a February 2025 analysis that Europe's smaller share of global biopharmaceutical research and development was associated with drug price controls. PhRMA cited the analysis in its arguments against MFN pricing.
Competitive Landscape
Seven other organizations lobbied on H.R. 1672: Public Citizen Inc., the ALS Association, Novartis AG, Ionis Pharmaceuticals Inc., Mended Hearts Inc., Novartis Corp. and Genentech Inc. The organizations represent pharmaceutical manufacturers, patient advocacy groups and consumer advocates with potentially differing interests in Medicare drug price negotiations. Their inclusion in lobbying disclosures does not, by itself, establish whether each organization supports or opposes the legislation.
The Bottom Line
Alnylam's in-house lobbying expenditures increased from $390,000 in the fourth quarter of 2025 to $470,000 in the third quarter. Its third-quarter 2023 filing also identified Medicare home infusion coverage and IRA implementation among the issues on which it lobbied.
Provisions associated with H.R. 4993, the Joe Fiandra Access to Home Infusion Act, were included in H.R. 7148, which became Public Law 119-75 on Feb. 3, according to the supplied legislative information. Meanwhile, H.R. 1672 remains at the committee-referral stage in the supplied record, as Alnylam continues lobbying on federal policies affecting drug pricing, reimbursement, and pharmaceutical innovation.
Access the Legis1 platform for comprehensive political news, data, and insights
Spot something wrong? Report an issue with this article
